COMPASS Pathways (NASDAQ:CMPS) shares are up during Tuesday’s premarket session following the company’s announcement of achieving the primary endpoint in its Phase 3 COMP006 trial for treatment-resistant depression.

Depression Data

The company reported that in the 25 mg arm of its trial, there was a statistically significant reduction in symptom severity for treatment-resistant depression.

In COMP006, two doses of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity with a mean difference of -3.8 comparing 25 mg to 1 mg (p<0.001).

Clinically meaningful reduction in MADRS (≥ 25%) observed in a significant number of participants in the 25mg arm of both trials, with 25% in COMP005 and 39% in COMP006, a proprietary formulation of psilocybin.

Additionally, the data suggest that COMP360 is generally well-tolerated, with most treatment-emergent adverse events being mild or moderate. The company is advancing discussions with the FDA to submit a New Drug Application (NDA) in Q4 2026, which could pave the way for new treatment options in a space with limited alternatives.

In June 2025, COMPASS Pathways shared data from the Phase 3 COMP005 trial. A single dose of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity compared to placebo.

Technical Analysis

Currently, the stock is trading 31.15% above its 12-month performance, reflecting strong momentum.

The shares are positioned closer to their 52-week highs than lows, indicating bullish sentiment among investors.

The RSI is at a neutral level, while the MACD is below its signal line, suggesting bearish pressure on the stock. This combination indicates mixed momentum, as the stock has not yet established a clear trend direction.

• Key Resistance: $8.00
• Key Support: $6.00

Analyst Consensus & Recent Actions

The stock carries a Buy rating with an average price target of $18.15. Recent analyst moves include:

• RBC Capital: Outperform (Raises Target to $21)
• Morgan Stanley: Overweight (Raises Target to $11)
• BTIG: Buy (Raises Target to $14)

Top ETF Exposure

• ADVISORSHARES PSYCHEDELICS ETF (NYSE:PSIL): 8.62% Weight

CMPS Price Action: Compass Pathways shares were up 23.06% at $7.15 during premarket trading on Tuesday, according to Benzinga Pro data.

Image via Shutterstock